Dual versus single antiplatelet therapy after lower extremity revascularization in peripheral artery disease: A systematic review and meta-analysis

Table 1 Characteristics of included studies comparing dual antiplatelet therapy and single antiplatelet therapy in patients with peripheral artery disease undergoing revascularization

Ref.	Study type	Intervention	DAPT drug name	DAPT duration	SAPT	Follow up
Rodriguez Alvarez et al[9], 2025	Prospective cohort	DAPT and SAPT	Aspirin and clopidogrel	4 weeks	Aspirin or clopidogrel	6 months
Armstrong et al[21], 2015	Retrospective cohort	N/A	Aspirin and clopidogrel, prasugrel, ticagrelor	N/A	Aspirin	3 years
Belch et al[18], 2010	RCT	Endovascular revascularization	Aspirin and clopidogrel	N/A	Aspirin	2 years
Belkini et al[26], 2020	Retrospective cohort	Bypass	Aspirin and clopidogrel, prasugrel, ticagrelor	N/A	Aspirin	1 year
Chinai et al[24], 2020	Retrospective cohort	Endovascular revascularization	Aspirin and clopidogrel	N/A	Aspirin	1.5 years
Cho et al[5], 2019	Prospective cohort	Endovascular revascularization	Aspirin plus clopidogrel	≥ 6 months	Aspirin or clopidogrel	5 years
Ipema et al[25], 2020	Retrospective cohort	Infra-inguinal endovascular treatment	Acetylsalicylic acid and clopidogrel	12 months	Acetylsalicylic acid or clopidogrel	1 year
Scheinert et al[19], 2012	RCT	Endovascular revascularization	Aspirin and clopidogrel	12 months	Aspirin	2 years
Soden et al[22], 2016	Retrospective cohort	Lower extremity revascularization	Aspirin and P2Y12 antagonist	N/A	Aspirin or P2Y12 antagonist	1 year
Strobl et al[20], 2013	RCT	Endovascular therapy	Aspirin and clopidogrel	6 months	Aspirin	12 months
Thott et al[23], 2017	Retrospective cohort	Endovascular femoropopliteal stenting	Aspirin and clopidogrel	100 days	Aspirin	2 years
Yamada et al[13], 2024	Retrospective cohort	Endovascular therapy	Aspirin and clopidogrel or aspirin and prasugrel	1 month	Any one of aspirin, clopidogrel, prasugrel	2 years

DAPT: Dual antiplatelet therapy; N/A: Not applicable; RCT: Randomized controlled trial; SAPT: Single antiplatelet therapy.

Table 2 Baseline characteristics of patients in included studies comparing dual antiplatelet therapy and single antiplatelet therapy in peripheral artery disease

Ref.	Age (mean ± SD)		Current smoking		Type 2 diabetes mellitus		Hypertension		Hyperlipidemia/dyslipidemia		Coronary artery disease		Cerebrovascular disease (intracranial hemorrhage)		Chronic kidney disease/dialysis		Ankle-brachial index (mean)
	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT	DAPT	SAPT
Rodriguez Alvarez et al[9], 2025	70	66	11	6	35	24	6	8	53	32	29	19	12	7	6	6	N/A	N/A
Armstrong et al[21], 2015	67	67	265	212	187	126	299	236	N/A	N/A	195	126	N/A	N/A	N/A	N/A	0.51	0.53
Belch et al[18], 2010	66.5	65.6	38.8	36.4	37.4	38	70.1	70	50.4	48.8	38.4	31	N/A	N/A	N/A	N/A	0.44	0.46
Belkini et al[26], 2020	65.8	66.4	42.6	42	51.1	45.2	90.1	85.1	N/A	N/A	35.1	25.4	N/A	N/A	3.8	3.7	N/A	N/A
Chinai et al[24], 2020	N/A	N/A	N/A	N/A	71	222	97	303	N/A	N/A	N/A	N/A	25	55	N/A	N/A	N/A	N/A
Cho et al[5], 2019	68.6	70.5	181	198	177	274	224	309	141	163	176	184	N/A	N/A			N/A	N/A
Ipema et al[25], 2020	68.7	74.4	75	99	40	68	58	98	61	65	N/A	N/A	N/A	N/A	3	5	N/A	N/A
Scheinert et al[19], 2012	68.6	70.5	34	21	24	32	12	23	N/A	N/A	12	34	N/A	N/A	21	11	0.52	0.47
Soden et al[22], 2016	68.1	67.8	37.1	38.2	45.2	44.8	87.9	88.5	N/A	N/A	31.1	30.5	N/A	N/A	6.4	5.9	N/A	N/A
Strobl et al[20], 2013	69.8	70.2	15	17	12	18	31	31	25	25	11	15	6	9	N/A	N/A	0.61	0.61
Thott et al[23], 2017	78	80	303	590	603	242	1054	488	N/A	N/A	N/A	N/A	59	169	133	49	N/A	N/A
Yamada et al[13], 2024	73.8	75.6	30	38	96	90	136	127	104	93	13	20	3	4	44	51	N/A	N/A

DAPT: Dual antiplatelet therapy; N/A: Not applicable; RCT: Randomized controlled trial; SAPT: Single antiplatelet therapy.